Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 17/20 | 0.61 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.48 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.43 |
| ▸ | FEN1 | P39748 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7050796 | 0.86 | GRIA4 (0.54) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL7026830 | 0.85 | GRIA4 (0.74) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL7045948 | 0.77 | ALOX5AP (0.39) | ALOX5APFEN1 | |
| SCHEMBL5878098 | 0.76 | GRIA4 (1.00) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL32681164 | 0.76 | GRIA4 (1.00) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6563447 | 0.75 | GRIA4 (0.59) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5992693 | 0.74 | GRIA4 (0.87) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL13255761 | 0.74 | GRIA4 (0.87) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5877988 | 0.74 | GRIA4 (1.00) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5877848 | 0.74 | GRIA4 (0.72) | GRIA4GRIA2GRIA1GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220369-A1 | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function | FORMAN SCOTT LOUIS (US) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220369-A1 | Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function | GRIN2A, GRIN1, GRIN2B | GRIA4 14/4885GRIA2 5/4885GRIA1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.